Skip to search formSkip to main contentSkip to account menu

BIIB021

Known as: BIIB-021 
National Institutes of Health

Related topics

Related topics

1 relation

Broader (1)

HSP90 inhibitor CNF2024

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2019
2019
Hsp90 inhibition in adrenocortical carcinoma: Limited drug synergism with mitotane
Review
2017
Review
2017
BIIB021: A novel inhibitor to heat shock protein 90–addicted oncology
Heat shock protein 90 is induced in response to the cell stress. Its overexpression has been reported in many cancers with poor… 
2015
2015
The potent activation of Ca(2+)-activated K(+) current by NVP-AUY922 in the human pancreatic duct cell line (PANC-1) possibly independent of heat shock protein 90 inhibition.
2013
2013
Metabolism and Excretion of 6-Chloro-9-(4-methoxy-3,5-dimethylpyridin-2-ylmethyl)-9H-purin-2-ylamine, an HSP90 Inhibitor, in Rats and Dogs and Assessment of Its Metabolic Profile in Plasma of Humans
6-Chloro-9-(4-methoxy-3,5-dimethyl-pyridin-2-ylmethyl)-9H-purin-2-ylamine (BIIB021), a synthetic HSP90 inhibitor, exhibited… 
2012
2012
In Vitro Metabolism of BIIB021, an Inhibitor of Heat Shock Protein 90, in Liver Microsomes and Hepatocytes of Rats, Dogs, and Humans and Recombinant Human Cytochrome P450 Isoforms
Inhibition of heat shock protein 90 (HSP90) results in the degradation of oncoproteins that drive malignant progression and… 
2011
2011
Biogen Idec restructures, sharpens neurology focus
It seems odd for a company in good financial health to undertake a dramatic restructuring, but Biogen Idec of Weston… 
2010
2010
Abstract P3-14-02: Phase 1 Dose-Escalation Study of the Heat Shock Protein 90 Inhibitor BIIB021 with Trastuzumab in HER2+ Metastatic Breast Cancer
Background: BIIB021 is an oral, fully synthetic heat shock protein 90 inhibitor (Hsp90i) that selectively and potently inhibits… 
2009
2009
Cancer Therapy : Preclinical CUDC-305 , a Novel Synthetic HSP 90 Inhibitor with Unique Pharmacologic Properties for Cancer Therapy
Purpose:We designed and synthesized CUDC-305, an HSP90 inhibitor of the novel imidazopyridine class. Here, we report its unique… 
2008
2008
BIIB021, an oral, synthetic non-ansamycin Hsp90 inhibitor: Phase I experience
2503 Background: BIIB021 is an oral fully synthetic Hsp90 inhibitor that is being developed for both solid and hematologic tumors… 
2007
2007
BIIB021 is a small molecule inhibitor of the heat shock protein, Hsp90, that shows potent anti-tumor activity in preclinical models
B161 Hsp90 is a widely-expressed molecular chaperone that functions in the maturation and stabilization of cellular proteins… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)